Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OVM-200 |
Synonyms | |
Therapy Description |
OVM-200 is a cancer vaccine comprised of peptides derived from survivin, which may induce cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing survivin (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OVM-200 | OVM200|OVM 200 | OVM-200 is a cancer vaccine comprised of peptides derived from survivin, which may induce cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells expressing survivin (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05104515 | Phase I | OVM-200 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | Recruiting | GBR | 0 |